A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
NCT05788926 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22
Last updated 2025-07-09
Summary
This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).
Conditions
Interventions
- DRUG
-
TG6050
Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
Sponsors & Collaborators
-
Transgene
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-05
- Primary Completion
- 2025-06-23
- Completion
- 2025-06-23
Countries
- France
Study Locations
More Related Trials
-
TG4010 and Nivolumab in Patients With Lung Cancer
NCT02823990 ·Status: COMPLETED ·Phase: PHASE2
-
Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
NCT02075957 ·Status: UNKNOWN
-
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
NCT04940325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT03087448 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
NCT06840782 ·Status: RECRUITING ·Phase: PHASE3
-
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
NCT05400577 ·Status: WITHDRAWN ·Phase: PHASE2
-
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
NCT06790303 ·Status: TERMINATED ·Phase: PHASE2
-
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
NCT00020202 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
NCT02323126 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
NCT02495636 ·Status: WITHDRAWN ·Phase: PHASE2
-
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00096486 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT02869789 ·Status: COMPLETED ·Phase: PHASE4
-
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT06249282 ·Status: RECRUITING ·Phase: PHASE1
-
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
NCT02642042 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
NCT01159327 ·Status: TERMINATED ·Phase: PHASE2
-
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
NCT00312975 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
NCT00760929 ·Status: TERMINATED ·Phase: PHASE2
-
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
NCT05311709 ·Status: RECRUITING ·Phase: PHASE2
-
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
NCT02706626 ·Status: TERMINATED ·Phase: PHASE2
-
Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)
NCT00419042 ·Status: COMPLETED
-
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT02132884 ·Status: TERMINATED ·Phase: NA
-
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
NCT04964479 ·Status: UNKNOWN ·Phase: PHASE3